Chemed Co. (NYSE:CHE – Get Free Report) was the recipient of a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 350,100 shares, a growth of 15.4% from the May 15th total of 303,500 shares. Approximately 2.4% of the company’s stock are sold short. Based on an average daily volume of 79,700 shares, the short-interest ratio is currently 4.4 days.
Chemed Price Performance
Shares of CHE opened at $538.66 on Tuesday. The company’s fifty day moving average price is $570.54 and its 200-day moving average price is $591.38. The firm has a market capitalization of $8.16 billion, a PE ratio of 28.99, a price-to-earnings-growth ratio of 2.22 and a beta of 0.46. Chemed has a 1-year low of $492.84 and a 1-year high of $654.62.
Chemed (NYSE:CHE – Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The company reported $4.68 EPS for the quarter, missing the consensus estimate of $5.09 by ($0.41). The business had revenue of $589.23 million during the quarter, compared to analysts’ expectations of $587.18 million. Chemed had a net margin of 12.36% and a return on equity of 30.52%. As a group, research analysts anticipate that Chemed will post 21.54 EPS for the current fiscal year.
Chemed Dividend Announcement
Wall Street Analyst Weigh In
Several research analysts have issued reports on CHE shares. Royal Bank of Canada dropped their target price on Chemed from $712.00 to $697.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 21st. Oppenheimer upped their target price on shares of Chemed from $625.00 to $650.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Finally, StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th.
View Our Latest Analysis on CHE
Insider Activity
In related news, VP Brian C. Judkins sold 11,158 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total value of $7,196,910.00. Following the sale, the vice president now owns 1,422 shares in the company, valued at approximately $917,190. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Brian C. Judkins sold 11,158 shares of the company’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $645.00, for a total value of $7,196,910.00. Following the transaction, the vice president now owns 1,422 shares in the company, valued at approximately $917,190. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kevin J. Mcnamara sold 4,000 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $567.54, for a total transaction of $2,270,160.00. Following the sale, the chief executive officer now owns 108,549 shares of the company’s stock, valued at $61,605,899.46. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,592 shares of company stock worth $13,424,584. Insiders own 3.32% of the company’s stock.
Institutional Trading of Chemed
A number of hedge funds and other institutional investors have recently modified their holdings of CHE. Kayne Anderson Rudnick Investment Management LLC grew its position in Chemed by 3.4% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 534,123 shares of the company’s stock valued at $277,584,000 after acquiring an additional 17,487 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Chemed by 0.3% during the 3rd quarter. Wellington Management Group LLP now owns 386,237 shares of the company’s stock worth $200,727,000 after buying an additional 1,044 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Chemed by 9.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 287,386 shares of the company’s stock valued at $149,355,000 after buying an additional 24,161 shares during the period. TD Asset Management Inc boosted its holdings in Chemed by 23.9% in the first quarter. TD Asset Management Inc now owns 254,953 shares of the company’s stock valued at $163,662,000 after purchasing an additional 49,176 shares during the period. Finally, FMR LLC grew its position in shares of Chemed by 15.4% during the third quarter. FMR LLC now owns 214,994 shares of the company’s stock worth $111,732,000 after buying an additional 28,682 shares in the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
See Also
- Five stocks we like better than Chemed
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Strong Buy Stocks for a Sizzling Summer Rally
- How to Choose Top Rated Stocks
- Kraft Heinz Stock Rises as Analysts Firm Up Sentiment
- What Does Downgrade Mean in Investing?
- Buffett Bails on BYD: What It Means for the Future of EV Stocks
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.